An exploratory study evaluating the effects of a single administration of NYX-2925 versus placebo on synaptic plasticity, a biological measure of changes in neural cell communication
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2018
At a glance
- Drugs NYX 2925 (Primary)
- Indications Fibromyalgia; Neurological disorders; Neuropathic pain
- Focus Pharmacodynamics
- 28 Nov 2018 New trial record
- 12 Nov 2018 According to an Aptinyx media release, the company plans to submit the detailed results of the study for publication and presentations at future scientific and medical meetings.
- 12 Nov 2018 Results presented in an Aptinyx the media release.